Cialis vs Alprostadil (Caverject/MUSE): Side-Effect Profile Head-to-Head

How These Two Drugs Work Differently

Tadalafil and alprostadil treat erectile dysfunction through entirely separate mechanisms, and those mechanisms shape their side-effect profiles. Understanding the pharmacology explains why one drug causes headaches while the other causes penile pain.

Tadalafil: Systemic PDE5 Inhibition

Tadalafil blocks phosphodiesterase type 5 (PDE5) throughout the body. PDE5 is expressed in penile smooth muscle but also in vascular beds, the GI tract, and skeletal muscle 1. This broad distribution is why tadalafil produces systemic effects: headache from cranial vasodilation, dyspepsia from GI smooth-muscle relaxation, and back pain from PDE5 inhibition in paraspinal muscles. The FDA label notes that tadalafil also weakly inhibits PDE11, which may contribute to myalgia at higher doses 2.

Alprostadil: Local Prostaglandin Action

Alprostadil (prostaglandin E1) acts directly on smooth muscle cells in the corpus cavernosum, increasing intracellular cyclic AMP and relaxing trabecular smooth muscle 3. Because it is delivered locally (by injection or urethral pellet), systemic absorption is minimal. Fewer than 2% of patients in the Linet et al. Key trial experienced systemic effects like dizziness or hypotension 3. The trade-off: local delivery concentrates side effects at the injection or insertion site.

Tadalafil Side Effects in Detail

In the Brock et al. (2002) dose-ranging study of 1,112 men, tadalafil 10 mg and 20 mg were well tolerated over 12 weeks. The side-effect profile is predictable and dose-dependent 1.

Frequency of Common Adverse Events

| Adverse event | Tadalafil 10 mg | Tadalafil 20 mg | Placebo | |---|---|---|---| | Headache | 13% | 15% | 5% | | Dyspepsia | 5% | 8% | 1% | | Back pain | 4% | 6% | 3% | | Nasal congestion | 3% | 5% | 2% | | Flushing | 2% | 3% | 1% | | Myalgia | 2% | 4% | 1% |

Source: Brock et al., J Urol 2002 1.

Headache and dyspepsia typically resolve within 12-24 hours without treatment. Back pain and myalgia are more specific to tadalafil than to sildenafil or vardenafil, likely because of tadalafil's longer half-life (17.5 hours) and its affinity for PDE11 2.

Serious but Rare Risks

Tadalafil is absolutely contraindicated with nitrates. Co-administration can cause severe, potentially fatal hypotension 4. The FDA label also includes a warning about non-arteritic anterior ischemic optic neuropathy (NAION), although a causal link has not been established and the incidence in PDE5 inhibitor users matches the general population rate of 2.5-11.8 per 100,000 men over age 50 5. Sudden sensorineural hearing loss has been reported in post-marketing surveillance but remains extremely rare 2.

Alprostadil Side Effects in Detail

Alprostadil's side-effect profile differs substantially depending on whether the drug is delivered by intracavernosal injection (Caverject, Edex) or intraurethral suppository (MUSE). The injection formulation concentrates the drug in cavernosal tissue and produces a stronger local response.

Caverject (Intracavernosal Injection)

Linet et al. (1996) enrolled 296 men in a double-blind, placebo-controlled study of intracavernosal alprostadil. The most reported side effect was penile pain, occurring in 37% of patients during at least one injection 3. Most described it as mild to moderate. Pain frequency decreased over time: by the sixth month of an open-label extension, only 12% of injections were associated with pain 6.

Other local effects in the Linet trial:

• Prolonged erection (>4 hours but <6 hours): 5% of patients 3
• Priapism (>6 hours requiring intervention): 1% 3
• Penile fibrosis/Peyronie-like nodules: 2-8% over 12 months of use 7
• Hematoma at injection site: 3-5% 3

Penile fibrosis is the most clinically significant long-term concern. A retrospective analysis by Lakin et al. (1998) found palpable nodules in 7.8% of men after a mean of 2.4 years of self-injection 7. The American Urological Association (AUA) recommends periodic penile examination for men on long-term injection therapy 8.

MUSE (Intraurethral Suppository)

MUSE delivers alprostadil to the urethral mucosa, resulting in lower cavernosal drug concentrations than direct injection. The MUSE key trial reported penile pain in 32.7% of patients, urethral burning in 12.4%, and minor urethral bleeding in 4.8% 9. Priapism rates were lower than with injection (<0.1%), but MUSE produced more systemic absorption: hypotension occurred in 3.3% and dizziness in 1.9% of subjects 9. Female partners reported vaginal irritation in approximately 5.8% of cases, an effect unique to the intraurethral route 9.

Side-by-Side Comparison Table

| Parameter | Tadalafil (Cialis) | Alprostadil injection (Caverject) | Alprostadil suppository (MUSE) | |---|---|---|---| | Headache | 15% | <1% | <1% | | Penile pain | Rare | 37% | 33% | | Dyspepsia | 8% | Not reported | Not reported | | Flushing | 3% | <1% | <1% | | Priapism | <0.1% | 1-3% | <0.1% | | Penile fibrosis (long-term) | Not reported | 2-8% | Not reported | | Hypotension | With nitrates only | <1% | 3.3% | | Discontinuation due to AEs | 3-5% | 9-12% | 6-8% |

Sources: 1, 2, 3, 9.

Who Tolerates Which Drug Better

The answer depends on the patient's comorbidities, medication list, and tolerance for local vs. Systemic effects.

Patients Who May Do Better on Tadalafil

Men who want a non-invasive, on-demand or daily oral option and have no contraindications to PDE5 inhibitors are typical first-line candidates. The AUA guidelines recommend PDE5 inhibitors as first-line pharmacotherapy for ED 8. Daily tadalafil 5 mg also has an FDA indication for benign prostatic hyperplasia (BPH), making it a practical two-for-one option in men with both conditions 2. Men who are needle-averse or who travel frequently often prefer tadalafil for convenience.

Patients Who May Do Better on Alprostadil

Alprostadil is a second-line therapy typically reserved for men who fail PDE5 inhibitors or have contraindications to them. It is the strongest option for men who take nitrates for coronary artery disease, since alprostadil does not interact with nitrates 10. In the Linet trial, alprostadil injection produced satisfactory erections in approximately 70% of men, including those who had previously failed oral therapy 3. Men after radical prostatectomy, who often have poor response to PDE5 inhibitors due to cavernous nerve damage, may achieve better results with intracavernosal alprostadil 11.

Managing and Minimizing Side Effects

Practical dose titration and patient education can reduce the burden of adverse events with either drug.

Reducing Tadalafil Side Effects

Starting at 10 mg (half the maximum dose) allows assessment of tolerability before escalation. For men who develop back pain or myalgia on as-needed 20 mg dosing, switching to daily 5 mg often resolves these effects because steady-state plasma levels are lower than peak levels after a 20 mg dose 12. Taking tadalafil with food does not affect absorption but may reduce dyspepsia. A 2005 pooled analysis of 11 tadalafil trials (N=3,325) confirmed that adverse events decreased after the first four weeks of therapy in most patients 12.

Reducing Alprostadil Side Effects

Penile pain is the primary barrier to long-term compliance with alprostadil. Dose titration in the clinician's office (starting at 2.5 mcg for Caverject and increasing in 2.5-5 mcg increments) reduces the risk of priapism and allows identification of the minimum effective dose 8. Some clinicians add 2% lidocaine to the injection mixture, which reduced pain scores by approximately 40% in a small randomized trial 13. Alternating injection sites between the left and right corpora and limiting injections to three per week helps prevent fibrosis 8.

For MUSE, urinating immediately before pellet insertion improves urethral mucosal absorption and may reduce burning. The manufacturer recommends applying a constriction ring at the base of the penis after insertion to retain the drug in the cavernosal tissue 9.

Switching Between Tadalafil and Alprostadil

There is no required washout period between these two drugs because they work through separate pathways. A man who stops tadalafil today can attempt alprostadil the next day. The reverse is also true. The clinical concern is not pharmacokinetic interaction but rather ensuring the new therapy is properly titrated.

Switching from Tadalafil to Alprostadil

The most common reason for this switch is PDE5 inhibitor failure, which occurs in approximately 30-40% of men with ED 14. The initial alprostadil dose should be titrated in-office regardless of the patient's prior tadalafil dose, because there is no dose equivalence between the two drugs. The AUA recommends starting Caverject at 2.5 mcg in neurogenic ED (e.g., post-prostatectomy) and 10 mcg in vasculogenic ED, then titrating upward 8.

Switching from Alprostadil to Tadalafil

Men who develop penile fibrosis or find injections intolerable may want to try (or retry) oral therapy. Even men who failed PDE5 inhibitors initially may respond after a period of alprostadil-induced improved penile blood flow, a concept sometimes called penile rehabilitation 15. Starting with tadalafil 5 mg daily for 4-8 weeks before reassessing gives the best chance of detecting a late response.

Drug Interactions and Safety Considerations

Tadalafil Interaction Profile

The nitrate interaction is the most dangerous. All organic nitrates (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite) are absolutely contraindicated 2. Alpha-blockers can produce additive hypotension; the FDA label recommends stable alpha-blocker dosing before starting tadalafil and beginning at the lowest tadalafil dose 2. CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) increase tadalafil exposure, potentially amplifying side effects 2.

Alprostadil Interaction Profile

Alprostadil has fewer systemic drug interactions because of minimal systemic absorption. The primary safety rule: do not combine alprostadil injection with other vasoactive intracavernosal agents (papaverine, phentolamine) unless using a standardized bi-mix or tri-mix protocol under physician supervision 8. Men on anticoagulants (warfarin, apixaban, rivaroxaban) face a higher risk of injection-site hematoma and should apply firm pressure for 3-5 minutes after injection 8.

What the Evidence Does Not Tell Us

No randomized, double-blind trial has directly compared tadalafil with alprostadil in the same patient population using the same endpoints. Cross-trial comparison is the best available evidence, but it has limits. The Brock 2002 and Linet 1996 studies enrolled different populations, used different primary endpoints, and were conducted six years apart 1, 3. The side-effect frequencies cited here reflect each drug's key data, not a direct head-to-head measurement.

The patterns are consistent across dozens of subsequent studies. PDE5 inhibitors reliably produce systemic vasodilatory effects. Alprostadil reliably produces local penile effects. These profiles have been stable for over two decades of post-marketing surveillance 2, 8.